Argenx Se Exceeds Expectations with Vyvgart Sales, Driving Buy Rating with Promising Pipeline and Market Expansion

Argenx Se's Vyvgart sales exceeded expectations in Q2, reaching $949mln, surpassing consensus estimates. The company is experiencing robust market expansion, with 15,000 patients globally. The pipeline is also promising, with five Phase 3 catalysts expected by 2026. Analyst Yaron Werber maintained a Buy rating and raised the price target to $800.

Argenx SE (NASDAQ: ARGX), a biotechnology company focused on autoimmune diseases, has reported strong second-quarter (Q2) 2025 earnings, with Vyvgart sales exceeding expectations. The company's Vyvgart revenues reached $949 million, surpassing consensus estimates of $863 million and BofA Securities' estimate of $885 million. This performance represents a 20% quarter-over-quarter (QoQ) growth rate and an impressive 82% year-over-year (YoY) growth rate [1].

The robust sales performance can be attributed to several factors, including the strong global demand for Vyvgart and the company's strategic expansion into new markets. Argenx has seen a significant increase in patient starts following the April launch of its pre-filled syringe option, which allows for convenient at-home dosing. This has expanded the company's reach to approximately 150 new Vyvgart prescribers, contributing to the growth in patient numbers [1].

Argenx's pipeline also holds promise for future growth. The company is advancing five Phase 3 catalysts by the end of 2026, including ARGX-119, a muscle-specific kinase (MuSK) agonist, and Empasiprubart, a C2-targeting monoclonal antibody. These pipeline assets reinforce Argenx's position as a leader in FcRn biology and complement its broader strategy to address underserved autoimmune populations [3].

Analyst Yaron Werber maintained a Buy rating and raised the price target for Argenx to $800, reflecting the company's strong performance and promising pipeline. Werber noted that Vyvgart is approaching $1 billion in global quarterly sales with further growth potential through indication expansion [1].

Despite the strong performance, Argenx faces risks, including clinical trial failures and competitive pressures in autoimmune diseases. However, the company's diversified pipeline and first-mover position in several indications provide a solid foundation for future growth [3].

In other news, Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused drug development company, has secured a $2 million private placement (PIPE) with institutional investors at a 5% premium to the July 31, 2025, closing price. The proceeds will support the clinical development of two key programs: paxalisib and EVT801 [2].

References:
[1] https://za.investing.com/news/analyst-ratings/bofa-securities-raises-argenx-stock-price-target-to-880-on-strong-vyvgart-sales-93CH-3814719
[2] https://www.stocktitan.net/news/KZIA/kazia-therapeutics-announces-2-million-private-placement-at-premium-x3iyd9nfw2bu.html
[3] https://www.ainvest.com/news/argenx-q2-2025-earnings-catalyst-long-term-growth-autoimmune-disease-innovation-2507/